

## Anti-TNFSF2/TNFA Antibody (CertolizumAb)

### Introduction

Certolizumab pegol (Certolizumab) is a recombinant, pegylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ). Certolizumab pegol is indicated for research in rheumatoid arthritis and Crohn's disease.

### Product parameters

Alternative Names	Certolizumab pegol, Cimzia, CDP870
Target Accession	P01375
Target	TNFSF2 / TNFA
CAS number	428863-50-7
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 $\mu$ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.



### **APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

